The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices deferred voting on a proposal to delay the first hepatitis B vaccine dose for infants born to mothers negative for hepatitis B infection. The panel cited ambiguity and remaining safety concerns, amid controversy surrounding recent committee restructuring, which has critics worried about the erosion of established vaccine guidelines. The vote postponement maintains the status quo for now, preserving early protection against hepatitis B in newborns.